GABAB receptors

Overview

Functional GABAB receptors are formed from the heterodimerization of two similar 7TM subunits termed GABAB1 and GABAB2 [1,2,3,4,5]. GABAB receptors are widespread in the CNS and regulate both pre- and postsynaptic activity. The GABAB1 subunit, when expressed alone, binds both antagonists and agonists, but the affinity of the latter is generally 10-100-fold less than for the native receptor. Co-expression of GABAB1 and GABAB2 subunits allows transport of GABAB1 to the cell surface and generates a functional receptor that can couple to signal transduction pathways such as high-voltage-activated Ca2+ channels (Cav2.1, Cav2.2), or inwardly rectifying potassium channels (Kir3) [6,1,7]. The GABAB1 subunit harbours the GABA (orthosteric)-binding site within an extracellular domain (ECD) venus flytrap module (VTM), whereas the GABAB2 subunit mediates G protein-coupled signalling [1,2,8,9]. The cryo-electron microscopy structures of the human full-length GABAB1-GABAB2 heterodimer have been solved in the inactive apo state, two intermediate agonist-bound forms and an active state in which the heterodimer is bound to an agonist and a positive allosteric modulator [10]. The positive allosteric modulator binds to the transmembrane dimerization interface and stabilizes the active state. Recent evidence indicates that higher order assemblies of GABAB receptor comprising dimers of heterodimers occur in recombinant expression systems and in vivo and that such complexes exhibit negative functional cooperativity between heterodimers [11,12]. Adding further complexity, KCTD (potassium channel tetramerization proteins) 8, 12, 12b and 16 associate as tetramers with the carboxy terminus of the GABAB2 subunit to impart altered signalling kinetics and agonist potency to the receptor complex [13,14,15] and are reviewed by [16]. The molecular complexity of GABAB receptors is further increased through association with trafficking and effector proteins [17] and reviewed by [18]. The predominant GABAB1a and GABAB1b isoforms, which are most prevalent in neonatal and adult brain tissue respectively, differ in their ECD sequences as a result of the use of alternative transcription initiation sites. GABAB1a-containing heterodimers localise to distal axons and mediate inhibition of glutamate release in the CA3-CA1 terminals, and GABA release onto the layer 5 pyramidal neurons, whereas GABAB1b-containing receptors occur within dendritic spines and mediate slow postsynaptic inhibition [19,20]. Amyloid precursor protein (APP) and soluble APP (sAPP) bind to the N- terminal sushi domain of the GABAB1a isoform to regulate axonal trafficking of GABAB receptors and release of neurotransmitters [21].

References

  1. Bowery NG, Bettler B, Froestl W, et al. International Union of Pharmacology. XXXIII. Mammalian gamma-aminobutyric acid(B) receptors: structure and function. Pharmacol Rev 2002;54:247-64.
  2. Pin JP, Kniazeff J, Binet V, et al. Activation mechanism of the heterodimeric GABA(B) receptor. Biochem Pharmacol 2004;68:1565-72.
  3. Emson PC. GABA(B) receptors: structure and function. Prog Brain Res 2007;160:43-57.
  4. Pin JP, Neubig R, Bouvier M, et al. International Union of Basic and Clinical Pharmacology. LXVII. Recommendations for the recognition and nomenclature of G protein-coupled receptor heteromultimers. Pharmacol Rev 2007;59:5-13.
  5. Ulrich D, Bettler B. GABA(B) receptors: synaptic functions and mechanisms of diversity. Curr Opin Neurobiol 2007;17:298-303.
  6. Bowery NG, Enna SJ. gamma-aminobutyric acid(B) receptors: first of the functional metabotropic heterodimers. J Pharmacol Exp Ther 2000;292:2-7.
  7. Bettler B, Kaupmann K, Mosbacher J, et al. Molecular structure and physiological functions of GABA(B) receptors. Physiol Rev 2004;84:835-67.
  8. Geng Y, Xiong D, Mosyak L, et al. Structure and functional interaction of the extracellular domain of human GABA(B) receptor GBR2. Nat Neurosci 2012;15:970-8.
  9. Geng Y, Bush M, Mosyak L, et al. Structural mechanism of ligand activation in human GABA(B) receptor. Nature 2013;504:254-9.
  10. Shaye H, Ishchenko A, Lam JH, et al. Structural basis of the activation of a metabotropic GABA receptor. Nature 2020;584:298-303.
  11. Pin JP, Comps-Agrar L, Maurel D, et al. G-protein-coupled receptor oligomers: two or more for what? Lessons from mGlu and GABAB receptors. J Physiol (Lond.) 2009;587:5337-44.
  12. Comps-Agrar L, Kniazeff J, Nørskov-Lauritsen L, et al. The oligomeric state sets GABA(B) receptor signalling efficacy. EMBO J 2011;30:2336-49.
  13. Turecek R, Schwenk J, Fritzius T, et al. Auxiliary GABAB receptor subunits uncouple G protein βγ subunits from effector channels to induce desensitization. Neuron 2014;82:1032-44.
  14. Bartoi T, Rigbolt KT, Du D, et al. GABAB receptor constituents revealed by tandem affinity purification from transgenic mice. J Biol Chem 2010;285:20625-33.
  15. Schwenk J, Metz M, Zolles G, et al. Native GABA(B) receptors are heteromultimers with a family of auxiliary subunits. Nature 2010;465:231-5.
  16. Pinard A, Seddik R, Bettler B. GABAB receptors: physiological functions and mechanisms of diversity. Adv Pharmacol 2010;58:231-55.
  17. Schwenk J, Pérez-Garci E, Schneider A, et al. Modular composition and dynamics of native GABAB receptors identified by high-resolution proteomics. Nat Neurosci 2016;19:233-42.
  18. Pin JP, Bettler B. Organization and functions of mGlu and GABAB receptor complexes. Nature 2016;540:60-68.
  19. Pérez-Garci E, Gassmann M, Bettler B, et al. The GABAB1b isoform mediates long-lasting inhibition of dendritic Ca2+ spikes in layer 5 somatosensory pyramidal neurons. Neuron 2006;50:603-16.
  20. Vigot R, Barbieri S, Bräuner-Osborne H, et al. Differential compartmentalization and distinct functions of GABAB receptor variants. Neuron 2006;50:589-601.
  21. Rice HC, de Malmazet D, Schreurs A, et al. Secreted amyloid-β precursor protein functions as a GABABR1a ligand to modulate synaptic transmission. Science 2019;363:.
Excerpt from IUPHAR/BPS Guide to Pharmacology
Species
Family
Panel
Download Catalog
Filters Sort results
Reset Apply
Species
Receptor
Family
Assays
Human
Available
Assay modes:
Agonist
Inverse agonist
Antagonist
PAM
NAM
Panels:
Human non-orphan GPCRs
Psychiatry
Neurology
Musculoskeletal
à la carte
Reference agonist:
baclofen
EC50:
9.4 µM
Human
Available
Assay modes:
Agonist
Inverse agonist
Antagonist
PAM
NAM
Panels:
Human non-orphan GPCRs
Psychiatry
Neurology
Musculoskeletal
à la carte
Reference agonist:
baclofen
EC50:
9.4 µM
Mouse
Available
Assay modes:
Agonist
Inverse agonist
Antagonist
PAM
NAM
Panels:
Mouse non-orphan GPCRs
à la carte
Reference agonist:
baclofen
EC50:
1.7 µM
Mouse
Available
Assay modes:
Agonist
Inverse agonist
Antagonist
PAM
NAM
Panels:
Mouse non-orphan GPCRs
à la carte
Reference agonist:
baclofen
EC50:
1.7 µM